M&A Deal Summary

Apposite Capital Acquires CrestOptics

On November 11, 2021, private equity firm Apposite Capital acquired machinery company CrestOptics

Acquisition Highlights
  • This is Apposite Capital’s 1st transaction in the Machinery sector.
  • This is Apposite Capital’s 1st transaction in Italy.

M&A Deal Summary

Date 2021-11-11
Target CrestOptics
Sector Machinery
Buyer(s) Apposite Capital
Deal Type Buyout (LBO, MBO, MBI)
Advisor(s) Chiomenti
Musumeci, Altara, Desana e Associati (Legal)

Target

CrestOptics

Rome, Italy
CrestOptics manufactures high-end microscopy instruments under its own brand and as an original equipment manufacturer (OEM). The Company’s instrumentation can be integrated with other high-end imaging systems used in life science research to enhance detection and imaging performance. CrestOptics was formed in 2009 and is based in Rome, Italy.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Apposite Capital

London, United Kingdom

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 2006
Size Small
Type Sector Focused
DESCRIPTION

Apposite Capital is a private investment firm focused on investing in growth companies in the healthcare sector. The Firm targets UK-based, revenue generating businesses and looks to invest £10 to £25 million over the life of an investment. Specific areas of interest include rehab services, primary and acute care companies, health related software solutions and IT, elderly and specialist healthcare services, medical products, and pharmaceuticals. Apposite Capital was established in 2006 and is based in London.


DEAL STATS #
Overall 16 of 19
Sector: Machinery M&A 1 of 1
Type: Buyout (LBO, MBO, MBI) M&A Deals 8 of 10
Country: Italy M&A 1 of 1
Year: 2021 M&A 5 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-08-02 i2a

Montpellier, France

i2a is a provider of instruments, software, and reagents for the clinical microbiology market in France. i2a specializes in offering automated solutions across the value chain of the bacteriology clinical testing market, including Antibiotic Sensitivity Testing which identifies bacterial resistance to antibiotics. i2a was founded in 1988 and is based in Montpellier, France.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-11-15 HCML

London, United Kingdom

HCML is a service provider in physical and psychological rehabilitation and case management, assisting injured and ill individuals to recover and return to work or to their pre-injury condition. HCML was founded in 2003 and is based in London, United Kingdom.

Buy -